Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

192.09 +2.64 (+1.39%)
Streaming Delayed Price Updated: 10:04 AM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat
AbbVie easily beat third-quarter expectations and raised its earnings outlook for the year. 
Via Investor's Business Daily
3 Dividend Growth Stocks to Buy and Never Sell
These 3 dividend growth stocks have crushed the market and show no signs of slowing down. 
Via The Motley Fool
Biotech Momentum Trades For The Q4 Rally
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
Via Talk Markets
AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings
AbbVie (ABBV) reports Q3 earnings Wednesday. The acquisition of Aliada Therapeutics may boost its Alzheimer's portfolio and stock, currently up 33.68% YTD. 
Via Benzinga
Sweetgreen, Tesla, Digital Realty Trust And A Health Care Stock On CNBC's 'Final Trades'
Sweetgreen shares closed at $37.48 during Friday's session. Analysts also discuss Tesla, AbbVie and Digital Realty Trust on 'Final Trades' 
Via Benzinga
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
Forecasting The Future: 11 Analyst Projections For AbbVie
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
3 Dividend Growth Stocks You Can Buy and Hold Forever
These healthcare stocks have fantastic dividend track records. 
Via The Motley Fool
3 High-Yielding Dividend Stocks That Can Be Ideal Buys for Retirees
These stocks yield between 2.8% and 3.3% in dividends. 
Via The Motley Fool
Beat the Nasdaq With This Cash-Gushing Dividend Stock
The company is performing well despite recently losing its biggest growth driver. 
Via The Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
These three Vanguard ETFs are worth considering for the long term. 
Via The Motley Fool
Topics ETFs
Market Analysis: AbbVie And Competitors In Biotechnology Industry
Via Benzinga
Looking Into AbbVie's Recent Short Interest
Via Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
Via Benzinga
AbbVie's Options: A Look at What the Big Money is Thinking
Via Benzinga
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
Via Talk Markets
3 Growth Stocks That Could Be Bargain Buys Right Now
These stocks trade at less than 20 times their estimated future profits. 
Via The Motley Fool
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
The FDA approved AbbVie's Vyalev as the first 24-hour subcutaneous infusion therapy for advanced Parkinson's disease, offering improved motor control and reduced symptoms. Approval was based on a... 
Via Benzinga
Exposures Product Safety
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
AbbVie Inc., which split from Abbott Laboratories remains more than a decade ago, is doing "very, very well," Jim Cramer says. 
Via Benzinga
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Private equity giants TPG and Blackstone are pursuing a potential $14 billion buyout of Bausch + Lomb. 
Via Benzinga
In-Depth Examination Of 11 Analyst Recommendations For AbbVie
Via Benzinga
2 Magnificent Dividend Stocks to Buy and Hold Forever
These companies have compelling track records. 
Via The Motley Fool
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
Buying these stocks gives you a great chance to beat the benchmark. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock. 
Via Talk Markets
There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors.
This Dividend King is beyond Buffett's reach to fully acquire and is a great pick for income investors. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
Via Benzinga
Biotech Stocks Poised For Another Big Move In Q4
The healthcare sector can be a safe haven if volatility increases. 
Via Talk Markets
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
3 Magnificent Dividend Stocks to Buy in October
These dividend stocks are great picks as the fall season gets underway. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.